NO872233L - Fremgangsmaate for fremstilling av farmasoeytiske preparater - Google Patents

Fremgangsmaate for fremstilling av farmasoeytiske preparater Download PDF

Info

Publication number: NO872233L
Authority: NO; Norway
Prior art keywords: compound; preparation; treatment; asthma; eosinophil
Prior art date: 1986-05-29

Application number

NO872233A

Other languages

English (en)

Norwegian (no)

Other versions

NO872233D0 (no

Inventor

John Morley

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-05-29

Filing date

1987-05-27

Publication date

1987-11-30

1987-05-27 Application filed by Sandoz Ag filed Critical Sandoz Ag

1987-05-27 Publication of NO872233D0 publication Critical patent/NO872233D0/no

1987-11-30 Publication of NO872233L publication Critical patent/NO872233L/no

Links

238000000034 method Methods 0.000 title claims description 43
238000002360 preparation method Methods 0.000 title claims description 36
239000000825 pharmaceutical preparation Substances 0.000 title claims description 15
238000011282 treatment Methods 0.000 claims description 58
210000003979 eosinophil Anatomy 0.000 claims description 56
208000006673 asthma Diseases 0.000 claims description 52
201000010099 disease Diseases 0.000 claims description 38
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
230000000694 effects Effects 0.000 claims description 23
206010003645 Atopy Diseases 0.000 claims description 18
208000023504 respiratory system disease Diseases 0.000 claims description 17
238000009825 accumulation Methods 0.000 claims description 16
230000002757 inflammatory effect Effects 0.000 claims description 16
206010014950 Eosinophilia Diseases 0.000 claims description 15
239000004480 active ingredient Substances 0.000 claims description 14
239000002552 dosage form Substances 0.000 claims description 12
206010035653 pneumoconiosis Diseases 0.000 claims description 11
206010006451 bronchitis Diseases 0.000 claims description 10
239000003085 diluting agent Substances 0.000 claims description 9
230000000414 obstructive effect Effects 0.000 claims description 9
239000007788 liquid Substances 0.000 claims description 8
239000007921 spray Substances 0.000 claims description 7
239000000969 carrier Substances 0.000 claims description 5
239000000443 aerosol Substances 0.000 claims description 4
239000006199 nebulizer Substances 0.000 claims description 4
150000001875 compounds Chemical class 0.000 description 126
229940124630 bronchodilator Drugs 0.000 description 32
229940079593 drug Drugs 0.000 description 30
239000003814 drug Substances 0.000 description 30
238000012360 testing method Methods 0.000 description 27
208000000884 Airway Obstruction Diseases 0.000 description 20
241001465754 Metazoa Species 0.000 description 17
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 16
108010003541 Platelet Activating Factor Proteins 0.000 description 16
238000002560 therapeutic procedure Methods 0.000 description 16
208000009079 Bronchial Spasm Diseases 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
230000035508 accumulation Effects 0.000 description 15
230000001154 acute effect Effects 0.000 description 15
206010006482 Bronchospasm Diseases 0.000 description 14
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 14
208000014181 Bronchial disease Diseases 0.000 description 13
230000036428 airway hyperreactivity Effects 0.000 description 13
239000000203 mixture Substances 0.000 description 12
230000000069 prophylactic effect Effects 0.000 description 12
230000004199 lung function Effects 0.000 description 11
241000700198 Cavia Species 0.000 description 10
230000001684 chronic effect Effects 0.000 description 10
239000000902 placebo Substances 0.000 description 10
229940068196 placebo Drugs 0.000 description 10
230000004044 response Effects 0.000 description 10
238000002636 symptomatic treatment Methods 0.000 description 9
206010013975 Dyspnoeas Diseases 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
238000011321 prophylaxis Methods 0.000 description 8
239000000126 substance Substances 0.000 description 8
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
208000000059 Dyspnea Diseases 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
229960001340 histamine Drugs 0.000 description 7
210000004072 lung Anatomy 0.000 description 7
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 7
238000005259 measurement Methods 0.000 description 7
230000002969 morbid Effects 0.000 description 7
229940043274 prophylactic drug Drugs 0.000 description 7
210000002345 respiratory system Anatomy 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
206010020751 Hypersensitivity Diseases 0.000 description 6
239000013566 allergen Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
230000008602 contraction Effects 0.000 description 6
238000011161 development Methods 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
150000003839 salts Chemical group 0.000 description 6
208000012657 Atopic disease Diseases 0.000 description 5
241000282414 Homo sapiens Species 0.000 description 5
230000009471 action Effects 0.000 description 5
230000000172 allergic effect Effects 0.000 description 5
208000010668 atopic eczema Diseases 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000001802 infusion Methods 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000000926 separation method Methods 0.000 description 5
239000003506 spasmogen Substances 0.000 description 5
230000001629 suppression Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
108010051479 Bombesin Proteins 0.000 description 4
241000700159 Rattus Species 0.000 description 4
210000000683 abdominal cavity Anatomy 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000004913 activation Effects 0.000 description 4
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 4
229960003556 aminophylline Drugs 0.000 description 4
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 4
239000003146 anticoagulant agent Substances 0.000 description 4
239000004044 bronchoconstricting agent Substances 0.000 description 4
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 4
229960004484 carbachol Drugs 0.000 description 4
210000000038 chest Anatomy 0.000 description 4
238000002651 drug therapy Methods 0.000 description 4
238000010253 intravenous injection Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
201000009732 pulmonary eosinophilia Diseases 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000029058 respiratory gaseous exchange Effects 0.000 description 4
229960002052 salbutamol Drugs 0.000 description 4
239000000243 solution Substances 0.000 description 4
210000003437 trachea Anatomy 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
102000013585 Bombesin Human genes 0.000 description 3
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000000556 agonist Substances 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
230000007815 allergy Effects 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 3
210000000621 bronchi Anatomy 0.000 description 3
230000003435 bronchoconstrictive effect Effects 0.000 description 3
239000000812 cholinergic antagonist Substances 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
229940088679 drug related substance Drugs 0.000 description 3
201000009580 eosinophilic pneumonia Diseases 0.000 description 3
208000024711 extrinsic asthma Diseases 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000011835 investigation Methods 0.000 description 3
230000007406 plaque accumulation Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
230000002040 relaxant effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
230000002048 spasmolytic effect Effects 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
208000037874 Asthma exacerbation Diseases 0.000 description 2
208000007596 Byssinosis Diseases 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010010741 Conjunctivitis Diseases 0.000 description 2
206010010744 Conjunctivitis allergic Diseases 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 2
206010061876 Obstruction Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
208000024780 Urticaria Diseases 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
230000009798 acute exacerbation Effects 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
238000011292 agonist therapy Methods 0.000 description 2
201000009961 allergic asthma Diseases 0.000 description 2
208000002205 allergic conjunctivitis Diseases 0.000 description 2
230000001088 anti-asthma Effects 0.000 description 2
230000002785 anti-thrombosis Effects 0.000 description 2
239000000924 antiasthmatic agent Substances 0.000 description 2
229960004676 antithrombotic agent Drugs 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
239000000168 bronchodilator agent Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
230000008859 change Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000009826 distribution Methods 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000002327 eosinophilic effect Effects 0.000 description 2
230000005713 exacerbation Effects 0.000 description 2
210000001508 eye Anatomy 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000000297 inotrophic effect Effects 0.000 description 2
239000013067 intermediate product Substances 0.000 description 2
201000010659 intrinsic asthma Diseases 0.000 description 2
229960001317 isoprenaline Drugs 0.000 description 2
229960004958 ketotifen Drugs 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 2
230000007774 longterm Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229960002748 norepinephrine Drugs 0.000 description 2
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
238000009117 preventive therapy Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
238000010992 reflux Methods 0.000 description 2
206010039083 rhinitis Diseases 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
208000033116 Asbestos intoxication Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
206010006473 Bronchopulmonary aspergillosis Diseases 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012455 Dermatitis exfoliative Diseases 0.000 description 1
206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
206010016228 Fasciitis Diseases 0.000 description 1
206010051011 Fibrinous bronchitis Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000020226 Heiner syndrome Diseases 0.000 description 1
206010019851 Hepatotoxicity Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
208000007924 IgA Deficiency Diseases 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
208000005615 Interstitial Cystitis Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
201000009324 Loeffler syndrome Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
241000101040 Pityriasis Species 0.000 description 1
102100024304 Protachykinin-1 Human genes 0.000 description 1
208000004430 Pulmonary Aspergillosis Diseases 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
102000040739 Secretory proteins Human genes 0.000 description 1
108091058545 Secretory proteins Proteins 0.000 description 1
206010039915 Selective IgA immunodeficiency Diseases 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
208000005279 Status Asthmaticus Diseases 0.000 description 1
206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
101800003906 Substance P Proteins 0.000 description 1
206010043087 Tachyphylaxis Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
206010065258 Tropical eosinophilia Diseases 0.000 description 1
206010046752 Urticaria Pigmentosa Diseases 0.000 description 1
206010047924 Wheezing Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000009102 absorption Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960001413 acetanilide Drugs 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
208000037883 airway inflammation Diseases 0.000 description 1
210000005091 airway smooth muscle Anatomy 0.000 description 1
235000013334 alcoholic beverage Nutrition 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
208000028462 aluminosis Diseases 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
208000010123 anthracosis Diseases 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
206010003441 asbestosis Diseases 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
208000024998 atopic conjunctivitis Diseases 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
229950006837 benafentrine Drugs 0.000 description 1
229940125388 beta agonist Drugs 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
230000003182 bronchodilatating effect Effects 0.000 description 1
230000007883 bronchodilation Effects 0.000 description 1
230000000572 bronchospasmolytic effect Effects 0.000 description 1
230000001593 cAMP accumulation Effects 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001587 cholestatic effect Effects 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000008828 contractile function Effects 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
208000018261 cutaneous leukocytoclastic angiitis Diseases 0.000 description 1
229960001270 d- tartaric acid Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000000586 desensitisation Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000428 dust Substances 0.000 description 1
230000002444 effect on eosinophils Effects 0.000 description 1
230000001424 embryocidal effect Effects 0.000 description 1
208000003401 eosinophilic granuloma Diseases 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
208000004526 exfoliative dermatitis Diseases 0.000 description 1
238000013265 extended release Methods 0.000 description 1
229960001022 fenoterol Drugs 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
201000005298 gastrointestinal allergy Diseases 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
230000010247 heart contraction Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
230000007686 hepatotoxicity Effects 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000002390 hyperplastic effect Effects 0.000 description 1
230000035874 hyperreactivity Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
206010021198 ichthyosis Diseases 0.000 description 1
208000013397 idiopathic acute eosinophilic pneumonia Diseases 0.000 description 1
201000007156 immunoglobulin alpha deficiency Diseases 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000003434 inspiratory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
201000006334 interstitial nephritis Diseases 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000009533 lab test Methods 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
238000012153 long-term therapy Methods 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
208000030179 maculopapular cutaneous mastocytosis Diseases 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
201000006512 mast cell neoplasm Diseases 0.000 description 1
208000006971 mastocytoma Diseases 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
DCDXHGMCXGHXBM-PMACEKPBSA-N n-[4-[(4as,10br)-8,9-dimethoxy-2-methyl-3,4,4a,10b-tetrahydro-1h-benzo[c][1,6]naphthyridin-6-yl]phenyl]acetamide Chemical compound N([C@H]1CCN(C)C[C@H]1C=1C=C(C(=CC=11)OC)OC)=C1C1=CC=C(NC(C)=O)C=C1 DCDXHGMCXGHXBM-PMACEKPBSA-N 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
230000008518 non respiratory effect Effects 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
208000007892 occupational asthma Diseases 0.000 description 1
208000014055 occupational lung disease Diseases 0.000 description 1
229940100688 oral solution Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
238000011170 pharmaceutical development Methods 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
208000018916 plastic bronchitis Diseases 0.000 description 1
230000009805 platelet accumulation Effects 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
210000004879 pulmonary tissue Anatomy 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
208000029138 selective IgA deficiency disease Diseases 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
208000013220 shortness of breath Diseases 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
208000004003 siderosis Diseases 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
230000003390 teratogenic effect Effects 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
210000005062 tracheal ring Anatomy 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
201000005539 vernal conjunctivitis Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO872233A 1986-05-29 1987-05-27 Fremgangsmaate for fremstilling av farmasoeytiske preparater NO872233L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB8613019		1986-05-29

Publications (2)

Publication Number	Publication Date
NO872233D0 NO872233D0 (no)	1987-05-27
NO872233L true NO872233L (no)	1987-11-30

Family

ID=10598604

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO872233A NO872233L (no)	1986-05-29	1987-05-27	Fremgangsmaate for fremstilling av farmasoeytiske preparater

Country Status (11)

Country	Link
EP (1)	EP0247971A3 (da)
JP (1)	JPS62294614A (da)
KR (1)	KR870011135A (da)
AU (1)	AU599981B2 (da)
DK (1)	DK273187A (da)
FI (1)	FI872360A (da)
IL (1)	IL82672A0 (da)
NO (1)	NO872233L (da)
NZ (1)	NZ220457A (da)
PT (1)	PT84953B (da)
ZA (1)	ZA873892B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY105344A (en) *	1990-05-16	1994-09-30	Byk Gulden Lomberg Chemische Fabrik	New sulphonyl compounds
WO1993009780A1 (de) *	1991-11-15	1993-05-27	Byk Gulden Lomberg Chemische Fabrik Gmbh	Verwendung von sulfonylverbindungen
SI0937074T1 (en) *	1996-11-11	2003-08-31	Altana Pharma Ag	Benzonaphthyridines as bronchial therapeutics
DE69817548T2 (de) *	1997-03-07	2004-06-17	Altana Pharma Ag	Tetrazole derivate
SI0988302T1 (en) *	1997-06-03	2003-08-31	Altana Pharma Ag	Benzonaphthyridines
JP2002513793A (ja) *	1998-05-05	2002-05-14	ビイクグルデンロンベルクヒエーミツシエフアブリークゲゼルシヤフトミツトベシユレンクテルハフツング	新規ｎ−オキシド

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5293796A (en) *	1976-01-30	1977-08-06	Sandoz Ag	Improvement in organic compound

1987
- 1987-05-20 EP EP87810305A patent/EP0247971A3/en not_active Withdrawn
- 1987-05-27 DK DK273187A patent/DK273187A/da not_active Application Discontinuation
- 1987-05-27 PT PT84953A patent/PT84953B/pt not_active IP Right Cessation
- 1987-05-27 FI FI872360A patent/FI872360A/fi not_active Application Discontinuation
- 1987-05-27 NO NO872233A patent/NO872233L/no unknown
- 1987-05-27 AU AU73437/87A patent/AU599981B2/en not_active Ceased
- 1987-05-27 NZ NZ220457A patent/NZ220457A/xx unknown
- 1987-05-27 IL IL82672A patent/IL82672A0/xx unknown
- 1987-05-28 JP JP62133242A patent/JPS62294614A/ja active Pending
- 1987-05-28 KR KR870005436A patent/KR870011135A/ko not_active Application Discontinuation
- 1987-05-29 ZA ZA873892A patent/ZA873892B/xx unknown

Also Published As

Publication number	Publication date
KR870011135A (ko)	1987-12-21
AU599981B2 (en)	1990-08-02
NO872233D0 (no)	1987-05-27
FI872360A (fi)	1987-11-30
PT84953B (pt)	1990-02-08
FI872360A0 (fi)	1987-05-27
PT84953A (en)	1987-06-01
EP0247971A3 (en)	1990-01-17
DK273187A (da)	1987-11-30
EP0247971A2 (en)	1987-12-02
IL82672A0 (en)	1987-11-30
AU7343787A (en)	1987-12-03
JPS62294614A (ja)	1987-12-22
DK273187D0 (da)	1987-05-27
NZ220457A (en)	1989-11-28
ZA873892B (en)	1989-01-25

Publication	Publication Date	Title
KR102722949B1 (ko)	2024-10-28	신경근 장애의 치료에 사용하기 위한 화합물
ES2966644T3 (es)	2024-04-23	Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia
WO2016028686A1 (en)	2016-02-25	Methods and compositions for the treatment of metabolic disorders
EP2802584A1 (en)	2014-11-19	Salts of an ip receptor agonist
JP2024509875A (ja)	2024-03-05	アルツハイマー病又は認知症を治療するための医薬組成物
BR112020005064A2 (pt)	2020-09-15	aminas beta-hidróxi heterocíclicas e seu uso no tratamento de hiperglicemia
US11793774B2 (en)	2023-10-24	Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia
CN113365628B (zh)	2024-11-19	使用离子通道抑制化合物治疗过敏性咳嗽或瘙痒的方法
KR20240116482A (ko)	2024-07-29	과혈당증 및 2형 당뇨병 치료를 위한 (r)-2-(tert-부틸아미노)-1-(5-플루오로피리딘-3-일)-에탄-1-올 헤미-타르트레이트 염의 결정질 형태
US9567347B2 (en)	2017-02-14	Use of small molecule inhibitors targeting the interaction between RAC GTPase and p67(phox)
NO872233L (no)	1987-11-30	Fremgangsmaate for fremstilling av farmasoeytiske preparater
EP3143005B1 (en)	2021-07-07	Chemokine cxcr4 and ccr5 receptor modulators and used related thereto
JPS6031833B2 (ja)	1985-07-24	新規な２０，２１↓−ジノルエブルナメニン誘導体、その製造法及び製薬組成物
TW202220956A (zh)	2022-06-01	新穎芳基氮雜雙環［２．１．１］己基甲醇及其醫藥用途
US10568852B2 (en)	2020-02-25	Combination compositions and their use in methods for treating obesity and obesity-related disorders
CN103483282B (zh)	2015-04-22	苯基取代的三唑酰胺类化合物及用途
JPH09291089A (ja)	1997-11-11	新規な５−チアゾリルウラシル誘導体又はその塩
EP3607948A1 (en)	2020-02-12	Tissue transglutaminase modulators for medicinal use
JPS62195392A (ja)	1987-08-28	ジヒドロピリジン−５−ホスホンアミド酸類
CN103467399B (zh)	2015-01-07	三唑酰胺类化合物、其制备方法和其用途
CN103467408B (zh)	2015-01-21	一类四氮唑羧酸类化合物及其用途
WO2024200777A1 (en)	2024-10-03	Substituted hydroxymethyl pyrrolidines for use in the treatment of hyperglycaemia and disorders characterised by hyperglycaemia
KR20240031421A (ko)	2024-03-07	메틸페니데이트-전구약물을 포함하는 조성물, 이를 제조 및 사용하는 방법
JP2014532077A (ja)	2014-12-04	抗糖尿病アミノステロイド誘導体
CN103467398A (zh)	2013-12-25	三唑酰胺类化合物、其制备方法和其抗糖尿病用途